22 May 2013
Keywords: tg, halts, tgaac94, trial, after, death, patient
Article | 06 August 2007
Seattle, USA-based biotechnology firm Targeted Genetics has reported the death of a trial volunteer who suffered a serious adverse event
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 August 2007
13 August 2007
21 May 2013
© 2013 thepharmaletter.com